Exclusion/inclusion criteria Patients with suspected glioblastoma multiforme based on 
clinical presentation and radiologic evaluation will be asked to particate in this trial. Patients will 
be asked for informed consent and entered into the protocol prior to surgery. 
Inclusion Criteria: 
1) Injection of transfected cells will not take place unless the tumor histopathology 
fulfills the criteria of glioblastoma multiforme and the cultured tumor cells 
demonstrate IGF-I production, as described above. 
2) Age > 18 years 
3) Completed course of radiotherapy (4500 cGy to the tumor with 3 cm margins and 1500 
cGy boost to tumor bed 
4) Glucocorticoids reduced to the lowest stable dose possible 
Exclusion Criteria: 
1) Histologically verified tumor other than glioblastoma multiforme 
2) Epstein/Barr virus antibody panels will be obtained on all potential study patients. 
Patients with panels consistent with active ongoing infection will be excluded. The 
reason for this exclusion is that we are introducing a vector that contains components of 
Epstein/Barr virus. These components in themselves will not reproduce viable virions. 
However, we do not want to study the possible interactions between the transfected 
element and ongoing infection. 
3) HIV antibody positive patients will also be excluded from this study. Although the 
vector used for transfection in these studies consists of components of Epstein /Barr virus 
DNA that do not include the immediate early region, previous work has shown that 
the immediate early gene products of some members of the herpes virus family can 
transactivate HIV promoter. 
4) Pregnancy testing will be performed on all eligible women. No pregnant woman will be 
entered into the study. 
5) Coagulopathy. Patients must have a prothrombin time (PT) and activated partial 
thromboplastin time (PTT) no greater than 1.4 x controls 
6) Thrombocytopenia. Platelet count must be >60,000/ mm3. 
7) Acute or active infection requiring treatment will delay or exclude patients depending 
on severity, type and treatment. 
8) Granulocytopenia. Total neutrophil count must be greater than 800/ mm^ 
9) Lymphopenia, total lymphocyte count must be greater than 500/mm^ 
10) Severe systemic disease. Lung or heart disease associated with an unacceptable 
anesthetic /operative risk will exclude patients rrom this study. 
11) Patients with a Kamofsky Score below 40 (see Attachment A) 
[ 140 ] 
Recombinant DNA Research, Volume 18 
